Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.
<h4>Background</h4>Serum lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3%) has been widely used for HCC diagnosis and follow-up surveillance as tumor serologic marker. However, the prognostic value of high pre-treatment serum AFP-L3% in patients with hepatocellular c...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0087011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849728158124736512 |
|---|---|
| author | Jiwen Cheng Wanli Wang Yingjun Zhang Xi Liu Muxing Li Zheng Wu Zhengwen Liu Yi Lv Bo Wang |
| author_facet | Jiwen Cheng Wanli Wang Yingjun Zhang Xi Liu Muxing Li Zheng Wu Zhengwen Liu Yi Lv Bo Wang |
| author_sort | Jiwen Cheng |
| collection | DOAJ |
| description | <h4>Background</h4>Serum lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3%) has been widely used for HCC diagnosis and follow-up surveillance as tumor serologic marker. However, the prognostic value of high pre-treatment serum AFP-L3% in patients with hepatocellular carcinoma (HCC) remains controversial. We therefore conduct a meta-analysis to assess the relationship between high pre-treatment serum AFP-L3% and clinical outcome of HCC.<h4>Methods</h4>Eligible studies were identified through systematic literature searches. A meta-analysis of fifteen studies (4,465 patients) was carried out to evaluate the association between high pre-treatment serum AFP-L3% and overall survival (OS) and disease-free survival (DFS) in HCC patients. Sensitivity and subgroup analyses were also conducted in this meta-analysis.<h4>Results</h4>Our analysis results showed that high pre-treatment serum AFP-L3% implied poor OS (HR: 1.65, 95%CI: 1.45-1.89 p<0.00001) and DFS (HR: 1.80, 95% CI: 1.49-2.17 p<0.00001) of HCC. Subgroup analysis revealed that there was association between pre-treatment serum AFP-L3% and endpoint (OS and DFS) in low AFP concentration HCC patients (HR: 1.96, 95% CI: 1.24-3.10, p = 0.004; HR: 2.53, 95% CI: 1.09-5.89, p = 0.03, respectively).<h4>Conclusion</h4>The current evidence suggests that high pre-treatment serum AFP-L3% levels indicated a poor prognosis for patients with HCC and AFP-L3% may have significant prognostic value in HCC patients with low AFP concentration. |
| format | Article |
| id | doaj-art-3727c9a2c9de4aab93ddf64fad7bfd1c |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-3727c9a2c9de4aab93ddf64fad7bfd1c2025-08-20T03:09:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8701110.1371/journal.pone.0087011Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.Jiwen ChengWanli WangYingjun ZhangXi LiuMuxing LiZheng WuZhengwen LiuYi LvBo Wang<h4>Background</h4>Serum lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3%) has been widely used for HCC diagnosis and follow-up surveillance as tumor serologic marker. However, the prognostic value of high pre-treatment serum AFP-L3% in patients with hepatocellular carcinoma (HCC) remains controversial. We therefore conduct a meta-analysis to assess the relationship between high pre-treatment serum AFP-L3% and clinical outcome of HCC.<h4>Methods</h4>Eligible studies were identified through systematic literature searches. A meta-analysis of fifteen studies (4,465 patients) was carried out to evaluate the association between high pre-treatment serum AFP-L3% and overall survival (OS) and disease-free survival (DFS) in HCC patients. Sensitivity and subgroup analyses were also conducted in this meta-analysis.<h4>Results</h4>Our analysis results showed that high pre-treatment serum AFP-L3% implied poor OS (HR: 1.65, 95%CI: 1.45-1.89 p<0.00001) and DFS (HR: 1.80, 95% CI: 1.49-2.17 p<0.00001) of HCC. Subgroup analysis revealed that there was association between pre-treatment serum AFP-L3% and endpoint (OS and DFS) in low AFP concentration HCC patients (HR: 1.96, 95% CI: 1.24-3.10, p = 0.004; HR: 2.53, 95% CI: 1.09-5.89, p = 0.03, respectively).<h4>Conclusion</h4>The current evidence suggests that high pre-treatment serum AFP-L3% levels indicated a poor prognosis for patients with HCC and AFP-L3% may have significant prognostic value in HCC patients with low AFP concentration.https://doi.org/10.1371/journal.pone.0087011 |
| spellingShingle | Jiwen Cheng Wanli Wang Yingjun Zhang Xi Liu Muxing Li Zheng Wu Zhengwen Liu Yi Lv Bo Wang Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS ONE |
| title | Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. |
| title_full | Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. |
| title_fullStr | Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. |
| title_full_unstemmed | Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. |
| title_short | Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. |
| title_sort | prognostic role of pre treatment serum afp l3 in hepatocellular carcinoma systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0087011 |
| work_keys_str_mv | AT jiwencheng prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT wanliwang prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT yingjunzhang prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT xiliu prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT muxingli prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT zhengwu prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT zhengwenliu prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT yilv prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis AT bowang prognosticroleofpretreatmentserumafpl3inhepatocellularcarcinomasystematicreviewandmetaanalysis |